Southern Research Institute

Intersect Ent Gmbh

The UAB Research Foundation (The University of Alabama at Birmingham)

US Government As Represented by the Secretary of the Army

Evonik Corporation

Stolle Research & Development Corporation

Clinuvel Pharmaceuticals Limited

Other

Tepha, Inc.

Syntex (u.s.a.) Inc.

Surmodics, Inc.

Cetus Corporation

Innovata Biomed Limited

Debiopharm S.a.

Genzyme Corporation

Thomas R Tice

Jay K Staas

Richard M Gilley

Rodney A Brenneman

Donald J Eaton

Patrick A Arensdorf

David B Downie

Danielle L Biggs

John H Eldridge

Danny H Lewis

Jean A Setterstrom

Peter Markland

Elliot Jacob

William E Meyers

John E Van Hamont

Robert H Reid

F Donald Roberts

Michael John Kleinig

Charles E McQueen

David W Mason

Phil Friden

Deborah L Dillon

Amanda McRae-McFarlane

Teresa M Ferrell

David P Martin

Lee R Beck

Donald R Cowsar

Frederick J Cassels

Curt Thies

Edgar C Boedeker

Kevin Burton

Gary Anthony Winchester

William M Shannon

William R Brown

Daniel L Jarboe

Ramasubbu Jeyanthi

Annica B Dahlstrom

Kevin W Burton

Arthur J Tipton

Andrew V Schally

Jerald C Sadoff

Danielle L Clay

Piero Orsolini

Paul R Sleath

Joseph M Magrath

Jack H Nunberg

Alan S Cross

Apurba K Bhattacharjee

Richard J Holl

Syamal Raychaudhuri

Wendell David Zollinger

Bruce W Hudson

John S Kent

Lynda M Sanders

Terrance A Taforo

Howard Bowman

Robert Nichol Boyes

Maninder Singh

Thomas O Dappert

Edgar C Boedecker

Ramassubbu Jeyanthi

Annica Dahlstromm

Torsten Woehr

Mimoun Ayoub

Melinda G Hollingshead

Michael E Hudson

Kenneth L Pledger

Laura L Williams

Rodney Brenneman

Described here are paranasal sinus devices for treating paranasal sinus conditions. The devices include a cavity member, ostial member, and nasal portion. One or more of the cavity member, ostial member, and nasal portion may deliver an active agent for sustained release to treat the paranasal sinus condition. Exemplary paranasal sinus conditions are sinus inflammation due to functional endoscopic sinus surgery (FESS) and rhinosinusitis.

Device and methods for treating paranasal sinus conditions

Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.

Methods of inducing melanogenesis in a subject

Compositions and methods of making and using of microparticle compositions that provide faster flow or improved injectability through smaller or small-diameter needles have been developed. Notably, the microparticle compositions can be successfully delivered or administered through smaller-diameter needles than other microparticle compositions prepared from biocompatible or biodegradable polymers including, for example, poly(lactide), poly(lactide-co-glycolide), polycaprolactone, or poly-3-hydroxybutyrate. The microparticle compositions can exhibit a higher solids loading for a given needle size and/or faster flow through needles than other microparticle compositions. Further, blending or mixing the polymer of the microparticle composition with other polymer formulations can enhance the injectability of the resulting formulation.

Injectable delivery of microparticles and compositions therefor

Disclosed herein are compositions comprising cross-linkers for cross-linking a retention vehicle polymer. The compositions are particularly useful for local administration of a bioactive agent, wherein prolonged or extended availability of the bioactive agent at the site of administration is desired. Also disclosed are methods of delivering the compositions to a subject.

Compositions and methods for improved retention of a pharmaceutical composition at a local administration site

Described herein are implantable composites, kits comprising the composites, implant devices comprising the composites, and methods of making and using same, including point of use methods.

Implantable suction cup composites and implants comprising same

Injectable delivery of microparticles and compositions therefore

Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.

Controlled-released peptide formulations

Flexible implantable composites and implants comprising same

Described here are devices, methods, and kits for treating sinusitis and related respiratory conditions by locally delivering active agents to the osteomeatal complex over a sustained period of time. The devices may be passively fixed within the osteomeatal complex and/or include one or more features that actively fix it within the osteomeatal complex. The devices may optionally include a portion that extends into a sinus ostium, sinus cavity, and/or the nasal passage to deliver an active agent.

Devices and methods for delivering active agents to the osteomeatal complex

Described herein are methods for reducing and achieving the desired release of an agent from a delivery system. The desired release kinetics are achieved by exposing the surface of the delivery system with a fluid for a desired period of time.

Methods for manufacturing delivery devices and devices thereof

Growing community of inventors

Indian Springs, AL, United States of America

Thomas R Tice